Yong-Zhi Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8749285/publications.pdf

Version: 2024-02-01

47 papers 2,530 citations

279798 23 h-index 233421 45 g-index

47 all docs

47 docs citations

times ranked

47

2877 citing authors

#	Article	IF	CITATIONS
1	Clinical practice guidelines for the management of adult diffuse gliomas. Cancer Letters, 2021, 499, 60-72.	7.2	194
2	A comprehensive model including preoperative peripheral blood inflammatory markers for prediction of the prognosis of diffuse spinal cord astrocytoma following surgery. European Spine Journal, 2021, 30, 2857-2866.	2.2	7
3	Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and evolution. Frontiers of Medicine, 2021, 15, 551-561.	3.4	39
4	Spinal Cord Diffuse Midline Gliomas With H3 K27m-Mutant: Clinicopathological Features and Prognosis. Neurosurgery, 2021, 89, 300-307.	1.1	18
5	METTL3 enhances the stability of MALAT1 with the assistance of HuR via m6A modification and activates NF-κB to promote the malignant progression of IDH-wildtype glioma. Cancer Letters, 2021, 511, 36-46.	7.2	86
6	YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF- $\hat{\mathbb{P}}$ B and promote the malignant progression of glioma. Journal of Hematology and Oncology, 2021, 14, 109.	17.0	92
7	Predictive value of MGMT promoter methylation on the survival of TMZ treated <i>IDH</i> -mutant glioblastoma. Cancer Biology and Medicine, 2021, 18, 271-282.	3.0	31
8	Interrogation of the microenvironmental landscape in spinal ependymomas reveals dual functions of tumor-associated macrophages. Nature Communications, 2021, 12, 6867.	12.8	19
9	Clinical characteristics of and treatment protocol for trapped temporal horn following resection of lateral ventricular trigone meningioma: a single-center experience. Journal of Neurosurgery, 2020, 132, 481-490.	1.6	9
10	Transcriptional Characteristics of IDH-Wild Type Glioma Subgroups Highlight the Biological Processes Underlying Heterogeneity of IDH-Wild Type WHO Grade IV Gliomas. Frontiers in Cell and Developmental Biology, 2020, 8, 580464.	3.7	8
11	Clinicopathological characteristics and survival of spinal cord astrocytomas. Cancer Medicine, 2020, 9, 6996-7006.	2.8	18
12	Brain Functional Differences in Drug-Naive Major Depression with Anxiety Patients of Different Traditional Chinese Medicine Syndrome Patterns: A Resting-State fMRI Study. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-9.	1.2	2
13	The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation. Acta Neuropathologica Communications, 2020, 8, 40.	5.2	51
14	Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas. CNS Neuroscience and Therapeutics, 2019, 25, 314-322.	3.9	42
15	A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide. Frontiers in Genetics, 2019, 10, 910.	2.3	22
16	Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma. Cancer Cell International, 2019, 19, 155.	4.1	27
17	Depression comorbid with hyperalgesia: Different roles of neuroinflammation induced by chronic stress and hypercortisolism. Journal of Affective Disorders, 2019, 256, 117-124.	4.1	26
18	Systematically characterize the clinical and biological significances of $1p19q$ genes in $1p/19q$ non-codeletion glioma. Carcinogenesis, 2019, 40, 1229-1239.	2.8	60

#	Article	IF	CITATIONS
19	m6A RNA methylation regulators contribute to malignant progression and have clinical prognostic impact in gliomas. Aging, 2019, 11, 1204-1225.	3.1	209
20	Differentiation of glioblastoma from solitary brain metastases using radiomic machine-learning classifiers. Cancer Letters, 2019, 451, 128-135.	7.2	128
21	Amino acid metabolismâ€related gene expressionâ€based risk signature can better predict overall survival for glioma. Cancer Science, 2019, 110, 321-333.	3.9	39
22	Brain activity in patients with deficiency versus excess patterns of major depression: A task fMRI study. Complementary Therapies in Medicine, 2019, 42, 292-297.	2.7	6
23	ADAMTSL4, a Secreted Glycoprotein, Is a Novel Immune-Related Biomarker for Primary Glioblastoma Multiforme. Disease Markers, 2019, 2019, 1-12.	1.3	66
24	A novel analytical model of MGMT methylation pyrosequencing offers improved predictive performance in patients with gliomas. Modern Pathology, 2019, 32, 4-15.	5.5	41
25	RNA processing genes characterize RNA splicing and further stratify lower-grade glioma. JCI Insight, 2019, 5, .	5.0	20
26	PATH-61. A NOVEL ANALYSIS MODEL OF MGMT METHYLATION PYROSEQUENCING OFFERS AN OPTIMAL PREDICTIVE PERFORMANCE IN GLIOMAS. Neuro-Oncology, 2018, 20, vi172-vi172.	1.2	0
27	Clinical Features, Radiologic Findings, and Surgical Outcomes of 65 Intracranial Psammomatous Meningiomas. World Neurosurgery, 2017, 100, 395-406.	1.3	9
28	Role of KCNB1 in the prognosis of gliomas and autophagy modulation. Scientific Reports, 2017, 7, 14.	3.3	68
29	miR-181d/MALT1 regulatory axis attenuates mesenchymal phenotype through NF-κB pathways in glioblastoma. Cancer Letters, 2017, 396, 1-9.	7.2	50
30	Post-craniotomy intracranial infection in patients with brain tumors: a retrospective analysis of 5723 consecutive patients. British Journal of Neurosurgery, 2017, 31, 5-9.	0.8	58
31	Tumor Location and Survival Outcomes in Adult Patients with Supratentorial Glioblastoma by Levels of Toll-Like Receptor 9 Expression. World Neurosurgery, 2017, 97, 279-283.	1.3	10
32	Stratification according to recursive partitioning analysis predicts outcome in newly diagnosed glioblastomas. Oncotarget, 2017, 8, 42974-42982.	1.8	8
33	Intracranial fibrous xanthoma mimicking a falcine meningioma. Neurology India, 2017, 65, 192.	0.4	0
34	Unusual presentation of an intracranial hemangiopericytoma as a cystic intraparenchymal mass lesion closely mimicking a glioma. Neurology India, 2017, 65, 208.	0.4	2
35	CGCG clinical practice guidelines for the management of adult diffuse gliomas. Cancer Letters, 2016, 375, 263-273.	7.2	448
36	Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas. Scientific Reports, 2016, 6, 21141.	3.3	29

3

#	Article	IF	CITATION
37	The Incidence and Risk Factors of Postoperative Entrapped Temporal Horn in Trigone Meningiomas. World Neurosurgery, 2016, 90, 511-517.	1.3	16
38	Upregulation of miR-181s reverses mesenchymal transition by targeting KPNA4 in glioblastoma. Scientific Reports, 2015, 5, 13072.	3.3	67
39	Hypomethylated Rab27b is a progression-associated prognostic biomarker of glioma regulating MMP-9 to promote invasion. Oncology Reports, 2015, 34, 1503-1509.	2.6	16
40	A MRS study of metabolic alterations in the frontal white matter of major depressive disorder patients with the treatment of SSRIs. BMC Psychiatry, 2015, 15, 99.	2.6	21
41	An Infrasellar Craniopharyngioma Involving the Sphenoid Sinus and Clivus. Chinese Medical Journal, 2015, 128, 844-845.	2.3	3
42	Correlation of preoperative seizures with clinicopathological factors and prognosis in anaplastic gliomas: A report of 198 patients from China. Seizure: the Journal of the British Epilepsy Association, 2014, 23, 844-851.	2.0	39
43	Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma. Neurosurgical Review, 2014, 37, 73-78.	2.4	21
44	Decreased Na+/K+ ATPase α1 (ATP1A1) gene expression in major depression patients' peripheral blood. Open Life Sciences, 2013, 8, 1077-1082.	1.4	1
45	Understanding high grade glioma: Molecular mechanism, therapy and comprehensive management. Cancer Letters, 2013, 331, 139-146.	7.2	228
46	Management and survival rates in patients with glioma in China (2004–2010): a retrospective study from a single-institution. Journal of Neuro-Oncology, 2013, 113, 259-266.	2.9	144
47	Inhibition of STAT3 reverses alkylator resistance through modulation of the AKT and \hat{l}^2 -catenin signaling pathways. Oncology Reports, 2011, 26, 1173-80.	2.6	32